Teicoplanin pharmacokinetics in pediatric patients

Pediatric Infectious Disease Journal

Volumn 15, Issue 6, 1996, Pages 494-498

  Dufort, Gustavo ^a   Ventura, Clara ^a   Olivé, Teresa ^a   Ortega, Juan J ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

pediatric patients; pharmacokinetics; Teicoplanin

Indexed keywords

AZTREONAM; BUSULFAN; CYCLOPHOSPHAMIDE; METICILLIN; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERANCE; GRAM NEGATIVE INFECTION; HUMAN; INCIDENCE; INFANT; MAINTENANCE THERAPY; NEUTROPENIA; PATIENT MONITORING; PRIORITY JOURNAL;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZTREONAM; BONE MARROW TRANSPLANTATION; CEFTAZIDIME; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MONOBACTAMS; TEICOPLANIN;

EID: 0029994076     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199606000-00005     Document Type: Article

References (26)

1. Bodey GP. Infections in cancer patients. Am J Med 1986;81(Suppl. 1A):11-26.
2. Patrick CC. Coagulase-negative staphylococci pathogens with increasing clinical significance. J Pediatr 1990;116:497-507.
3. Karp JE, Merz W, Dick JD, Saral R. Strategies to prevent or control infections after bone marrow transplants. Bone Marrow Transplant 1991;8:1-6.
4. Schaison GS, Leverger G, Arlet G, Peking M, Garand JJ. Treatment of coagulase-negative staphylococcal infection in neutropenic patients. Int Cong Symp Ser 1990;156:21-7.
5. Karp JE, Dick JD, Angelopulos C et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986;81:237-42.
6. Rubin M, Hathorn JW, Marshall D, Gress J, Steimberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
7. Rubin M, Pizzo PA. Antibiotics for the treatment of febrile children with neutropenia and cancer. N Engl J Med 1988;320:939.
8. Campoli-Richards DM, Brodgen RN, Faulds D. Teicoplanin: a review of its antibacterial activity, pharmacokinetics properties and therapeutic potential. Drugs 1990;40:449-86.
9. Wilson APR, Grüneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and USA. Int J Antimicrob Agents 1994;4(Suppl. 1):S1-30.
10. Lemerle S, de la Rocque F, Lamy R, et al. Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients. J Antimicrob Che- mother 1988;21(Suppl. A):113-6.
11. Tarral E, Jehl F, Tarral A, et al. Pharmacokinetics of teicoplanin in children. J Antimicrob Chemother 1988;21(Suppl A):47-51.
12. Peller P, Aichholzer B, Fell J, et al. Safety and efficacy of teicoplanin in the treatment of Gram-positive infections in patients in Germany. Pediatr Infect Dis J 1993;12:57-9.
13. Dagan R, Einborn M, Howard CB, Williams AH. Outpatient and impatient teicoplanin treatment for serous infections in children. Pediatr Infect Dis J 1993;12:S17-20.
14. Wilson AP, Gruneberg RN, Neu H. Dosage recommendation for teicoplanin. J Antimicrob Chemother 1993;32:792-6.
15. Goldstein FW, Controut A, Sieffer A, Acar JF. Percentages and distributions of teicoplanin and vancomycin resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 1990;34:899-900.
16. Barry AL, Jones RN, Gavan TL, Thornsberry C. Collaborative Antimicrobial Susceptibility Testing Group Quality Control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria. J Clin Microbiol 1987;25:1812-4.
17. Cox A, Whitby M, Nimmo G, Williams G. Evaluation of a novel fluorescence polarization immunoassay for teicoplanin. Antimicrob Agents Chemother 1993;37:1924-6.
18. Marion Merrel Dow Pharmaceuticals. Targocid. In: ABPI Data Sheet Compendium 1993-94. London: Datapharm Publications, 1994:936-8.
19. Gnansounou M, Nelken B, Vic P, et al. Pharmacokinetics of once-daily teicoplanin, amikacin, ceftriaxone and continuous infusion of vancomycin, ceftazydime plus once-daily amikacin in febrile neutropenic children [Abstract]. Med Pediatr Oncol 1995;25:288.
20. Rowland M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 1990;18:184-209.
21. Assandri A, Bernareggi A. Binding of teicoplanin to human serum albumin. Eur J Pharmacol 1987;33:191-5.
22. Thompson GA, Smithers JA, Kenny MT et al. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers. Biopharm Drug Dispos 1992;13:213-20.
23. Novakova I, Donnelly JP, De Daw B. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 1991;35:672-8.
24. Terragria A, Ferrea G, Loy A, et al. Pharmacokineties of teicoplanin in pediatric patients. Antimicrob Agents Chemother 1988;32:1223-6.
25. Kureishi A, Jewesson PJ, Barlett KH, Cole CD, Chow AW. Application of a modified bioassay for monitoring teicoplanin and vancomycin in febrile neutropenic patients. Antimicrob Agents Chemother 1990;334:1642-7.
26. Butler DR, Kuhn RJ, Chandler MH. Pharmacokinetics of anti-infective agents in paediatric patients. Clin Pharmacokinet 1994;26:374-95.